2011
DOI: 10.1111/j.1468-1331.2011.03618.x
|View full text |Cite
|
Sign up to set email alerts
|

Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity

Abstract: These findings show that BoNT/A injected into the detrusor muscle in patients with PD and SCI modulates bladder afferent activity. Modulation of bladder afferents possibly explains why BoNT/A improves detrusor overactivity.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
28
0

Year Published

2013
2013
2019
2019

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 30 publications
(30 citation statements)
references
References 30 publications
(40 reference statements)
1
28
0
Order By: Relevance
“…The selective β3-adrenoceptor agonist mirabegron [13], [14] has been recently proposed to treat OAB, however its effectiveness in patients with NDO remains uncertain. Newer therapies such as intravesical botulinum toxin [3], [15] are not only invasive and expensive but are also associated with safety concerns [3], [6], [16]. Therefore, novel approaches to treat NDO are urgently needed.…”
Section: Introductionmentioning
confidence: 99%
“…The selective β3-adrenoceptor agonist mirabegron [13], [14] has been recently proposed to treat OAB, however its effectiveness in patients with NDO remains uncertain. Newer therapies such as intravesical botulinum toxin [3], [15] are not only invasive and expensive but are also associated with safety concerns [3], [6], [16]. Therefore, novel approaches to treat NDO are urgently needed.…”
Section: Introductionmentioning
confidence: 99%
“…The long-term effectiveness of newer therapies such as mirabegron, a selective ␤ 3 -adrenoceptor agonist (6,9), and botulinum toxin (8,26,33) remains uncertain, and in some cases their use presents safety concerns (26,28). The lack of safe and universally effective OAB treatments continues to spur the scientific community to seek novel therapeutic approaches to control OAB.…”
mentioning
confidence: 96%
“…Therefore, the guarding time for these patients to prevent urinary incontinence could be shorter than that for OAB patients in general. Intravesical onabotulinumtoxinA injections decrease detrusor contractility and also modulate afferent fibers in NDO [25]. A higher dose of onabotulinumtoxinA could impair detrusor contractility and sensory input too much, causing large PVR volumes, difficult urination, or overflow incontinence.…”
Section: Discussionmentioning
confidence: 99%